There are different druggability profiles between murine PD-L1 and human PD-L1; thus, a PD-L1 humanized syngeneic tumor model is necessary for the evaluation of a human PD-L1 inhibitor (21, 22). The gene discussed is CD274; the disease is neoplasm.